Latest News and Press Releases
Want to stay updated on the latest news?
-
此次合作依托Tenacia在中枢神经系统（CNS）药物开发与商业化方面的专长，加速RAP-219在美国及全球的开发进程 Tenacia获得大中华区RAP-219开发和商业化的独家权利，针对病症包括局灶性发作癫痫和双相躁狂等适应症 Rapport将获得2000万美元的现金预付款，最高可达3.08亿美元的潜在开发与商业化里程碑款项及其他付款，以及个位数中段到十几中段的分级特许权使用费 ...
-
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
-
Rapport Therapeutics to Participate in Upcoming Investor Conferences
-
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second...
-
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’...
-
BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...
-
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline...
-
BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...
-
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...